Stock AnalizTango Therapeutics, Inc. TNGX
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Tango Therapeutics, Inc. (TNGX) is a healthcare company listed in the US with a market value of about $4.3B. In fiscal year 2025 it had revenue of $62M and net income of -$102M, a net margin of -162.9%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 52% a year, a 5-year average ROIC of -29%.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | $62M | $42M | $37M | $25M | $37M | $8M |
| Net income | -$102M | -$130M | -$102M | -$108M | -$58M | -$52M |
| Free cash flow | -$140M | -$132M | -$120M | -$117M | -$61M | $69M |
| EPS (diluted) | $-0.87 | $-1.19 | $-1.08 | $-1.23 | $-0.94 | $-1.63 |
| Net margin | -162.8% | -309.7% | -278.5% | -435.1% | -157.2% | -678.8% |
| ROIC | -23.2% | -48.7% | -31.1% | -30.2% | -13.3% | -112.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $47.00, 84% above the current price; targets range from $24.00 to $68.00; the consensus rating is “Strong buy”; expected EPS is $-1.46 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Tango Therapeutics pay a dividend?
Not currently.
Is Tango Therapeutics a good stock to buy?
We do not give buy or sell advice. Tango Therapeutics scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.